SLV 318

Drug Profile

SLV 318

Latest Information Update: 08 Mar 2010

Price : $50

At a glance

  • Originator Solvay
  • Class Antidepressants; Antiparkinsonians; Anxiolytics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 31 Jul 2003 A preclinical study has been added to the Parkinson's disease pharmacodynamics section ,
  • 18 Feb 2003 Data presented at the 7th International Congress of Parkinson's disease and Movement disorders [2002] have been added to the pharmacodynamics section
  • 31 Oct 2002 Preclinical trials in Parkinson's disease in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top